COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device
A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.
• adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.
‣ Written informed consent from patient or if not possible due to encephalopathy (\> grade 2): legal representative
⁃ acute-on-chronic liver failure (ACLF) grade ≥ 2:
• Acute decompensation event (identifiable trigger)
∙ Hepatic encephalopathy grade ≥ 2
∙ Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours)
∙ Serum bilirubin ≥ 10 mg/dl
∙ Hemodynamic instability with vasopressor support (norepinephrine \> 0.05 mcg/kg/min)